SCHEMBL449597

SCHEMBL449597

C1=Cc2ccccc2ON=N1

nearest known ligand 0.33

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
TRPA1 O75762 1/20 0.32
HTR2C P28335 1/20 0.30
HTR2B P41595 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4450135 0.84 KDM4E (0.30) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL4450134 0.84 KDM4E (0.30) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL4450130 0.84 KDM4E (0.30) KDM4EMEN1ALDH1A1MAPTKMT2A
Isoquinoline SCHEMBL16972854 0.82 TNF (0.30)
SCHEMBL209689 0.77 TRPA1 (0.34) TRPA1
SCHEMBL23400 0.77 KDM4E (0.35) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL7098395 0.67 MAPT (0.38) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL17164340 0.66
SCHEMBL17164341 0.66
SCHEMBL17164339 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 442 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024102758-A2 N-(N-AMINOALKYL)PHENANTHRIDIUNIUM SERIES OF CHLORIDE-SENSITIVE FLUOROPHORES AND METHODS OF USE THEREOF THE GENERAL HOSPITAL CORPORATION (US) 2024-05-16 WO claimed
EP-1852420-B1 Indole compounds for treating respiratory disorders ONO PHARMACEUTICAL CO (JP) 2012-10-17 EP claimed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 US claimed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US claimed
US-12600730-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2026-04-14 US disclosed
US-20260083735-A1 ABHD6 ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2026-03-26 US disclosed
EP-4596555-A1 ABHD6 ANTAGONIST ONO Pharmaceutical Co., Ltd. (JP) 2025-08-06 EP disclosed
CN-114605350-B Polymerizable compound, polymerizable composition containing same, and optically anisotropic body 江苏创拓新材料有限公司 2024-09-13 CN disclosed
US-20240270755-A1 SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2024-08-15 US disclosed
WO-2024102758-A2 N-(N-AMINOALKYL)PHENANTHRIDIUNIUM SERIES OF CHLORIDE-SENSITIVE FLUOROPHORES AND METHODS OF USE THEREOF THE GENERAL HOSPITAL CORPORATION (US) 2024-05-16 WO disclosed
US-11981682-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2024-05-14 US disclosed
WO-2024071398-A1 ABHD6 ANTAGONIST 小野薬品工業株式会社 2024-04-04 WO disclosed
EP-0900791-A1 TETRAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 1999-03-10 EP disclosed
WO-1998046590-A1 THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-10-22 WO disclosed
EP-0567090-A2 Benzoxazepine derivatives as cholinesterase inhibitors TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-10-27 EP disclosed
US-4062852-A CNS STIMULANTS E. R. SQUIBB & SONS, INC. (US) 1977-12-13 US disclosed
US-4062852-A CNS STIMULANTS E. R. SQUIBB & SONS, INC. (US) 1977-12-13 US disclosed
US-4003905-A Diels-alder adducts of benzdiazepines E. R. SQUIBB & SONS, INC. (US) 1977-01-18 US disclosed
US-3946025-A MUSCLE RELAXANTS E. R. SQUIBB & SONS, INC. (US) 1976-03-23 US disclosed
US-3886158-A 6H-pyrimido{8 1,2-c{9 {8 1,3,5{9 {0 benzoxadiazepines SQUIBB & SONS INC 1975-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270755-A1 SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS ABHD6, ABHD16A, PITHD1 KDM4E 1018/4885MEN1 4379/4885ALDH1A1 1199/4885
US-11981682-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ABHD6, ABHD16A, PITHD1 KDM4E 1038/4885MEN1 4364/4885ALDH1A1 1190/4885
US-12600730-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ABHD6, ABHD16A, HDHD5 KDM4E 1505/4885MEN1 4611/4885ALDH1A1 548/4885
US-20260083735-A1 ABHD6 ANTAGONIST ABHD6, ABHD16A, ABHD12 KDM4E 2124/4885MEN1 4097/4885ALDH1A1 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.